C	
L	

Zaponex Treatment Access System



F02.S04

This form is used to register as a pharmacist with the Zaponex Treatment Access System (ZTAS®). Pharmacists working at more than one location should submit a Pharmacist Data Form for each location. Please complete all sections. **INCOMPLETE FORMS WILL NOT BE PROCESSED**. We will use the information provided on this form in accordance with the terms of the ZTAS privacy notice which is available from the ZTAS website www.ztas.co.uk.

>>> PHARMACIST DATA FORM

Clozapine pharmacist

A pharmacist who is the primary contact for ZTAS in the pharmacy at the below address. A clozapine pharmacist can register other pharmacy staff ('proxies') at this pharmacy address and is responsible for updating ZTAS with any changes to any of these details.

Pharmacist

A pharmacist who is involved in the treatment of patients with Zaponex[®] (clozapine) and registered with ZTAS who is not the clozapine pharmacist at this pharmacy address.

Pharmacist Details Professional Registration Number * Please circle appropriate.	GPC	/ P	NI*									: = Gen = Pha								rela	nd					
Title		Pro	f		Mr			М	rs			Ms														
Name												SI	JR	N	A	M	E									
Type of contact		Clo	zapin	e pha	rmac	ist		P	harma	acist	t		Job 1	itle												
Emergency telephone number												ffice te umber		one		Y L	Y-				r					
Work email	j		h	٦ <u>.</u>	s	m	i t	h		n	h	s	. n	e	t	γ ,	γ		γ J		γ λ) L	۲ <u> </u>			
Please do not use group email address or gmail / yahoo etc.																										
Facility name								Υ								Υ <u></u>	Υ <u></u>	Υ	γ	Υ	γ	γ	۲ <u> </u>	γ	Υ	
Address																Ŷ	Y T		Ŷ		~		~			$\overline{)}$
Town/city														Pos	stco	de					~	~				

Notification standard (Clozapine pharmacist only)

ZTAS reminders, warnings and alerts will be sent to the registered email address of the Clozapine Pharmacist.

Registration of a group email address requires a Data Sharing Form to be completed and returned.

Adverse event reporting

The ZTAS routinely monitors blood results for abnormalities in WBC, Neutrophils, Eosinophils and Platelets. Abnormalities in these parameters (i.e. where outside agreed ZTAS ranges) are reported as adverse events to the Leyden Delta Drug Safety department, who may then contact the responsible healthcare professional for further details. Please note that adverse events should be reported. Reports of adverse events can be made to the MHRA directly via the Yellow Card scheme at www.mhra.gov.uk/yellowcard or the MHRA Yellow Card app. Adverse events should also be reported to Leyden Delta via info@ztas.co.uk or by calling 0207 3655 842.

DECLARATION

This document is my statement of intent to participate in the dispensing and monitoring of Zaponex[®] (clozapine) in association with the ZTAS. Signing of this form confirms my commitment to adhere to the Zaponex SPC and the ZTAS Manual. Signing of this form also constitutes a confirmation of my understanding of, and commitment to, my responsibilities in respect of maintaining the confidentiality of my patient's details and reporting adverse events, as detailed above. I understand that my registration will be confirmed by a return email which has instructions for me to access the ZTAS system, and that my details to access ZTAS should not be shared, in order to prevent unauthorised access to patient data. Should I no longer require access to the ZTAS, or if there are any changes to the patient data under my care, I will inform ZTAS of this within 30 days. I have read the ZTAS privacy notice and understand how my personal data will be used by Leyden Delta.

Prescribing reminders

Zaponex may only be prescribed by a Consultant who is registered with the ZTAS, or other ZTAS-approved prescriber.

- Zaponex may only be prescribed for patients who are registered with the ZTAS.
- There must always be a current, valid blood result for the patient before any Zaponex is dispensed.
- Zaponex may only be dispensed under the responsibility of a ZTAS registered clozapine pharmacist.

Date	d d - m m - y y y y	Signature	